title: Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
abstract: Immune responses against the Leishmania antigens are not sufficient to protect against a leishmania challenge. Therefore these antigens need to be potentiated by various adjuvants and delivery systems. In this study, Poly (d,l-lactide-co-glycolide (PLGA) nanospheres as antigen delivery system and Quillaja saponins (QS) as immunoadjuvant have been used to enhance the immune response against autoclaved Leishmania major (ALM). PLGA nanospheres were prepared by a double-emulsion (W/O/W) technique. Particulate characteristics were studied by scanning electron microscopy and particle size analysis. Mean diameter for nanospheres loaded with ALM+QS was 294 ± 106 nm. BALB/c mice were immunized three times in 3-weeks intervals using ALM plus QS loaded nanospheres [(ALM+QS)PLGA], ALM encapsulated with PLGA nanospheres [(ALM)PLGA], (ALM)PLGA + QS, ALM + QS, ALM alone or PBS. The intensity of infection induced by L. major challenge was assessed by measuring size of footpad swelling. The strongest protection, showed by significantly (P < 0.05) smaller footpad, were observed in mice immunized with (ALM)PLGA. The (ALM+QS)PLGA group showed the least protection and highest swelling, while the (ALM)PLGA+QS, ALM+QS and ALM showed an intermediate protection with no significant difference. The mice immunized with ALM and ALM+QS showed the highest IgG2a/IgG1 ratio (P < 0.01), followed by (ALM)PLGA+QS. The highest IFN-γ and lowest IL-4 production was seen in (ALM)PLGA+QS, ALM+QS groups. The highest parasite burden was observed in (ALM)PLGA+QS and (ALM+QS)PLGA groups. It is concluded that PLGA nanospheres as a vaccine delivery system could increase the protective immune responses, but QS adjuvant has a reverse effect on protective immune responses and the least protective responses were seen in the presence of this adjuvant.
authors.affiliation: Nanotechnology Research Center and School of Pharmacy, Mashhad University of Medical Sciences, PO Box 91775-1365, Mashhad, Iran.
authors.forename: M
authors.initials: M
authors.lastname: Tafaghodi
authors.forename: M
authors.initials: M
authors.lastname: Eskandari
authors.forename: M
authors.initials: M
authors.lastname: Kharazizadeh
authors.forename: A
authors.initials: A
authors.lastname: Khamesipour
authors.forename: M R
authors.initials: MR
authors.lastname: Jaafari
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D004337:Drug Carriers / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005260:Female; D005528:Foot / Q000473:pathology; D007114:Immunization / Q000379:methods; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D019344:Lactic Acid / Q000008:administration & dosage*; D007896:Leishmaniasis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008855:Microscopy, Electron, Scanning; D054118:Nanospheres / Q000008:administration & dosage* / Q000648:ultrastructure; D011100:Polyglycolic Acid / Q000008:administration & dosage*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D031990:Quillaja / Q000737:chemistry*; D012503:Saponins / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D004337:Drug Carriers; D007074:Immunoglobulin G; D054332:Leishmaniasis Vaccines; D012503:Saponins; C416262:autoclaved Leishmania major vaccine; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D015847:Interleukin-4; D011100:Polyglycolic Acid; D019344:Lactic Acid; D007371:Interferon-gamma